Stock 4594 BRIGHTPATH BIOTHERAPEUTICS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News BrightPath Biotherapeutics Co., Ltd.

Equities

4594

JP3274140007

Delayed Japan Exchange
Other stock markets
 01:10:33 2024-07-05 am EDT 		5-day change 1st Jan Change
63 JPY +12.50% Intraday chart for BrightPath Biotherapeutics Co., Ltd. +10.53% -27.59%
Jun. 19 BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥2.67 million in funding CI
2023 BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥5.1678 million in funding from Macquarie Group Limited CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥2.67 million in funding
CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥5.1678 million in funding from Macquarie Group Limited
CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥5.1678 million in funding from Macquarie Group Limited
CI
BrightPath Biotherapeutics Co., Ltd.(TSE:4594) dropped from S&P Global BMI Index
CI
BrightPath Biotherapeutics Presents Data on Personalized Neoantigen Cancer Vaccine
MT
BrightPath Biotherapeutics Presents Data on Antibody for Cancer Treatment
MT
BrightPath Biotherapeutics : Presents Preclinical Data on a CD73 antagonist antibody at AACR 2022
PU
BrightPath Biotherapeutics : Presents New Data on Personalized Neoantigen Vaccine at AACR 2022
PU
Brightpath Biotherapeutics Announces Preclinical Data on BP1209
CI
BrightPath Biotherapeutics : Presents New Data on Preclinical Data on BP2301(HER2 CAR-T) at AACR 2022
PU
BrightPath Biotherapeutics : Presents New Data on Personalized Neoantigen Vaccine at AACR 2022
PU
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm
CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥1.427175 billion in funding from Macquarie Bank Limited, Investment Arm
CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm
CI
BrightPath Biotherapeutics Co., Ltd. announced that it expects to receive ¥0.585974 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm
CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Six Months Ended September 30, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019
CI
Brightpath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2018; Provides Earnings Guidance for the Year Ending March 31, 2018
CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2018; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2019
CI
BrightPath Biotherapeutics Co., Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2017; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2018
CI
BrightPath Biotherapeutics Co., Ltd. announced that it has received ¥12.1744 million in funding from Credit Suisse Securities Limited, Investment Arm
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4594 Stock
  4. News BrightPath Biotherapeutics Co., Ltd.